Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk study shows reduced risk of death associated with Tresiba

Novo Nordisk study shows reduced risk of death associated with Tresiba

15th September 2017

Novo Nordisk has reported new clinical trial data that demonstrates how its drug Tresiba can help to reduce the risk of death in type 2 diabetes patients.

New analyses from the multinational DEVOTE trial demonstrated that people with type 2 diabetes who experience severe hypoglycaemia are at greater risk of death, with the risk being four times higher 15 days after an event and two-and-a-half times higher any time after an episode.

In addition, daily fluctuations in blood sugar levels in people with type 2 diabetes were also shown to be associated with a higher risk of death. Use of Tresiba reduced the rate of severe hypoglycaemia by 40 percent and the rate of nocturnal severe hypoglycaemia by 53 percent compared to another insulin type, meaning these risks were mitigated.

The findings echo those seen in the SWITCH 2 trial, in which Tresiba recipients experienced a 51 percent lower rate of severe hypoglycaemia during the full treatment period of the trial and a 42 percent reduction in the rate of nocturnal hypoglycaemia.

Dr Bernard Zinman of the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and the University of Toronto, said: "These results highlight the importance of maintaining low variability in blood sugar levels and reducing the risk of severe hypoglycaemia when treating people with type 2 diabetes."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801839933-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.